Loss of gm130 in breast cancer cells and its effects on cell migration, invasion and polarity

Cell Cycle

Volumn 14, Issue 8, 2015, Pages 1139-1147

  Baschieriab, Francesco ^a,b   Allmena, Edith Uetz Von ^a   Leglera, Daniel F ^a   Farhan, Hesso ^a,b  

^a UNIVERSITY OF KONSTANZ   (Switzerland)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GM130 PROTEIN; MATRIX PROTEIN; MESSENGER RNA; PROTEIN CDC42; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; AUTOANTIGEN; GOLGIN SUBFAMILY A MEMBER 2; MEMBRANE PROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER SURVIVAL; CELL ADHESION; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL POLARITY; CELL PROLIFERATION; CELL STRUCTURE; CHEMOTAXIS; CONTROLLED STUDY; GOLGI COMPLEX; HUMAN; HUMAN CELL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SURVIVAL; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL MOTION; DRUG EFFECTS; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; AUTOANTIGENS; BREAST NEOPLASMS; CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL POLARITY; CELL PROLIFERATION; DOXORUBICIN; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GOLGI APPARATUS; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84928036492     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1007771     Document Type: Article

References (33)

1. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends in Cell Biology 2006; 16:522-9.
2. Hall A. Rho family GTPases. Biochem Soc Trans 2012; 40:1378-82.
3. Etienne-Manneville S. Cdc42 - the centre of polarity. Journal ofCell Science 2004; 117:1291-300.
4. Wang F, Herzmark P, Weiner OD, Srinivasan S, Servant G, Bourne HR. Lipid products of PI(3)Ks maintain persistent cell polarity and directed motility in neutrophils. Nat Cell Biol 2002; 4:513-8.
5. Liu BP, Burridge K. Vav2 activates Rac1, Cdc42, and RhoA downstream from growth factor receptors but not beta1 integrins. Mol Cell Biol 2000; 20:7160-9.
6. Etienne-Manneville S, Hall A. Cdc42 regulates GSK-3 [beta] and adenomatous polyposis coli to control cell polarity. Nature 2003; 421:753-6.
7. Michaelson D, Silletti J, Murphy G, D'Eustachio P, Rush M, Philips MR. Differential Localization of Rho Gtpases in Live Cells: Regulation by Hypervariable Regions and Rhogdi Binding. The Journal of Cell Biology 2001; 152:111-26.
8. Erickson JW, Zhang C-j, Kahn RA, Evans T, Cerione RA. Mammalian Cdc42 Is a Brefeldin A-sensitive Component of the Golgi Apparatus. Journal of Biological Chemistry 1996; 271:26850-4.
9. Baschieri F, Confalonieri S, Bertalot G, Di Fiore PP, Dietmaier W, Leist M, et al. Spatial control of Cdc42 signalling by a GM130—RasGRF complex regulates polarity and tumorigenesis. Nat Commun 2014; 5.
10. Farhan H, Rabouille C. Signalling to and from the secretory pathway. Journal of Cell Science 2011; 124:171-80.
11. Yang G, Cynader MS. Regulation of protein trafficking: JNK3 at the Golgi complex. Cell Cycle 2014; 13:5-6.
12. Millarte V, Farhan H. The Golgi in cell migration: regulation by signal transduction and its implications for cancer cell metastasis. ScientificWorldJournal 2012; 2012:498-278.
13. Baschieri F, Farhan H. Crosstalk of small GTPases at the Golgi apparatus. Small GTPases 2012; 3:80-90.
14. McCaffrey Luke M, Montalbano J, Mihai C, Macara Ian G. Loss of the Par3 Polarity Protein Promotes Breast Tumorigenesis and Metastasis. Cancer Cell2012; 22:601-14.
15. Xue B, Krishnamurthy K, Allred DC, Muthuswamy SK. Loss of Par3 promotes breast cancer metastasis by compromising cell—cell cohesion. Nat Cell Biol 2013; 15:189-200.
16. Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB, et al. Deregulation of Scribble Promotes Mammary Tumorigenesis and Reveals a Role for Cell Polarity in Carcinoma. Cell 2008; 135:865-78.
17. Weller SG, Capitani M, Cao H, Micaroni M, Luini A, Sallese M, et al. Src kinase regulates the integrity and function of the Golgi apparatus via activation of dynamin 2. Proc NatlAcad SciUSA 2010; 107:5863-8.
18. Bard F, Mazelin L, Pechoux-Longin C, Malhotra V, Jurdic P. Src Regulates Golgi Structure and KDEL Receptor-dependent Retrograde Transport to the Endoplasmic Reticulum. Journal of Biological Chemistry 2003; 278:46601-6.
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74.
20. Qiao X, Roth I, Feraille E, Hasler U. Different effects of ZO-1, ZO-2 and ZO-3 silencing on kidney collecting duct principal cell proliferation and adhesion. Cell Cycle 2014; 13:3059-75.
21. Bilder D. Epithelial polarity and proliferation control: links from the Drosophila neoplastic tumor suppressors. Genes & Development 2004; 18:1909-25.
22. Gligorijevic B, Bergman A, Condeelis J. Multiparametric Classification Links Tumor Microenvironments with Tumor Cell Phenotype. PLoS Biol 2014; 12: e1001995.
23. Patsialou A, Bravo-Cordero JJ, Wang Y, Entenberg D, Liu H, Clarke M, et al. Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors. Intravital 2013;2:e25294.
24. Dang I, Gorelik R, Sousa-Blin C, Derivery E, Guerin C, Linkner J, et al. Inhibitory signalling to the Arp2/3 complex steers cell migration. Nature 2013; 503:281-4.
25. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer cell 2006; 10:515-27.
26. Ma B, van Blitterswijk CA, Karperien M. A Wnt/β-cat-enin negative feedback loop inhibits interleukin-1— induced matrix metalloproteinase expression in human articular chondrocytes. Arthritis & Rheumatism 2012; 64:2589-600.
27. Riaz M, Elstrodt F, Hollestelle A, Dehghan A, Klijn JG, Schutte M. Low-risk susceptibility alleles in 40 human breast cancer cell lines. BMC Cancer 2009; 9:236.
28. Kao J, Salari K, Bocanegra M, Choi Y-L, Girard L, Gandhi J, et al. Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery. PLoS ONE 2009; 4:e6146.
29. Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011; 30:3222-33.
30. Krypuy M, Ahmed A, Etemad moghadam D, Hyland S, Australian Ovarian Cancer Study G, deFazio A, et al.High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer 2007; 7:168.
31. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakra-varthy AB, Shyr Y, et al. Identification ofhuman triplenegative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation 2011; 121:2750-67.
32. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14:518-27.
33. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346-52.